Evidence map›Paper›PMID 27272312›Full record

ArticleWorld journal of urology2017

Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.

T A T Marcelissen, M S Rahnama'i, A Snijkers, B Schurch, P De Vries

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
  13. Urinary Incontinence and Pelvic Organ Prolapse in Women.Deutsches Arzteblatt international · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Promoting patient followup treatment with intra-detrusor onabotulinumtoxinA for overactive bladder.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

T A T MarcelissenDepartment of Urology, Zuyderland Medical Centre, Heerlen, The Netherlands.
M S Rahnama'iDepartment of Urology, Zuyderland Medical Centre, Heerlen, The Netherlands. sajjad_r@yahoo.com.
A SnijkersMaastricht University, Maastricht, The Netherlands.
B SchurchService de neuroréhabilitation, CHUV, Lausanne, Switzerland.
P De VriesDepartment of Urology, Zuyderland Medical Centre, Heerlen, The Netherlands.
Zuyderland Medisch Centrum · NLMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIntravesical botulinum toxin (BoNT-A) is a safe and effective treatment for overactive bladder syndrome. There are many reports on the clinical experience with BoNT-A, especially in patients with neurogenic detrusor overactivity. The US Food and Drug Administration has recently approved its use for idiopathic overactive bladder (iOAB). Various studies have reported positive results for iOAB in the short-term. Yet little is known about the results after repeated BoNT-A injections. In this study, we evaluated the long-term results of botulinum toxin (BoNT-A) in women with iOAB.

methodsPatients treated with BoNT-A from 2004 until 2009 were evaluated in a non-academic teaching hospital (Zuyderland MC, Heerlen, the Netherlands). All female patients with a follow-up of >5 years with idiopathic bladder dysfunction were included. All patients received 200 U of onabotulinum toxin-A in 20 intradetrusor injections. In some patients, we applied a dose adjustment for repeated injections. Patients were instructed how to use clean intermittent self-catheterization (CISC) before the treatment. We advised patients to commence CISC if post-void residual exceeded 150 ml.

resultsA total of 128 women were included. All patients had at least 5-year follow-up after their first injection. The mean follow-up was 97 (60-125) months. The mean age was 67 (46-88) years. Of all patients, 30 % were still on BoNT-A treatment at the last follow-up visit. Of the 70 % that discontinued treatment, 27 % had insufficient effect and 43 % had tolerability issues. Most patients discontinued treatment after the first (79 %) and second (19 %) injections. Only 2 % of patients discontinued treatment after more than two injections during follow-up.

conclusionIntravesical BoNT-A is an effective treatment for women with idiopathic OAB. However, in time, almost two-thirds of patients in our study discontinued therapy. Most patients discontinue treatment after one or two injections and mainly due to tolerability issues.

Indexed as

Acetylcholine Release InhibitorsAdministration, IntravesicalAgedAged, 80 and overBotulinum Toxins, Type AFemaleFollow-Up StudiesHumansMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeUrinary Bladder, OveractiveAcetylcholine Release InhibitorsBotulinum Toxins, Type ABladderBotoxBotulinum toxin ADetrusorDetrusor overactivityLUTSOveractive bladder

Identifiers

PMID27272312
OpenAlexW2416514211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.